Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN versus CLINDAMYCIN PALMITATE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN versus CLINDAMYCIN PALMITATE HYDROCHLORIDE.
CLEOCIN vs CLINDAMYCIN PALMITATE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation.
Clindamycin palmitate hydrochloride is a prodrug that is hydrolyzed in vivo to clindamycin. Clindamycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking peptide bond formation. It also inhibits the early stages of protein synthesis by interfering with the initiation complex.
150-450 mg orally every 6 hours; 300-600 mg IM or IV every 6-8 hours; maximum 4.8 g/day IV.
150-300 mg orally every 6 hours. Maximum dose: 1.8 g/day.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 8-12 hours in severe hepatic impairment; dialyzable but not clinically used for Clostridium difficile infection.
Terminal elimination half-life is approximately 2.4–3.0 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life may be prolonged up to 8–10 hours.
Approximately 10% renal as active drug and metabolites, 90% fecal/biliary via enterohepatic circulation; <1% unchanged in urine.
Approximately 10% of the dose is excreted unchanged in urine; the remainder is eliminated as inactive metabolites via bile (about 30–40%) and feces (about 50–60%). Renal clearance is minor and dosing adjustment is not typically required in renal impairment.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic